Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Translocator protein (TSPO) ligand-Ara-C (cytarabine) conjugates as a strategy to deliver antineoplastic drugs and to enhance drug clinical potential.

Denora N, Laquintana V, Trapani A, Lopedota A, Latrofa A, Gallo JM, Trapani G.

Mol Pharm. 2010 Dec 6;7(6):2255-69. doi: 10.1021/mp100235w. Epub 2010 Nov 8.

PMID:
20958082
2.

TSPO Ligand-Methotrexate Prodrug Conjugates: Design, Synthesis, and Biological Evaluation.

Laquintana V, Denora N, Cutrignelli A, Perrone M, Iacobazzi RM, Annese C, Lopalco A, Lopedota AA, Franco M.

Int J Mol Sci. 2016 Jun 18;17(6). pii: E967. doi: 10.3390/ijms17060967.

3.

PEG-Ara-C conjugates for controlled release.

Schiavon O, Pasut G, Moro S, Orsolini P, Guiotto A, Veronese FM.

Eur J Med Chem. 2004 Feb;39(2):123-33.

PMID:
14987821
4.

Anticancer activity of PEGylated matrix metalloproteinase cleavable peptide-conjugated adriamycin against malignant glioma cells.

Lim SH, Jeong YI, Moon KS, Ryu HH, Jin YH, Jin SG, Jung TY, Kim IY, Kang SS, Jung S.

Int J Pharm. 2010 Mar 15;387(1-2):209-14. doi: 10.1016/j.ijpharm.2009.11.023. Epub 2009 Nov 27.

PMID:
19945519
5.

Sustained delivery of cytarabine-loaded vesicular phospholipid gels for treatment of xenografted glioma.

Qi N, Cai C, Zhang W, Niu Y, Yang J, Wang L, Tian B, Liu X, Lin X, Zhang Y, Zhang Y, He H, Chen K, Tang X.

Int J Pharm. 2014 Sep 10;472(1-2):48-55. doi: 10.1016/j.ijpharm.2014.06.005. Epub 2014 Jun 7.

PMID:
24914829
6.

Synthesis and in vitro antitumor effect of vinblastine derivative-oligoarginine conjugates.

Bánóczi Z, Gorka-Kereskényi Á, Reményi J, Orbán E, Hazai L, Tökési N, Oláh J, Ovádi J, Béni Z, Háda V, Szántay C Jr, Hudecz F, Kalaus G, Szántay C.

Bioconjug Chem. 2010 Nov 17;21(11):1948-55. doi: 10.1021/bc100028z. Epub 2010 Oct 25.

PMID:
20973492
7.

Platinum(II) complexes with bioactive carrier ligands having high affinity for the translocator protein.

Margiotta N, Denora N, Ostuni R, Laquintana V, Anderson A, Johnson SW, Trapani G, Natile G.

J Med Chem. 2010 Jul 22;53(14):5144-54. doi: 10.1021/jm100429r.

PMID:
20568783
8.

Targeted cancer therapy: conferring specificity to cytotoxic drugs.

Chari RV.

Acc Chem Res. 2008 Jan;41(1):98-107. Epub 2007 Aug 18. Review.

PMID:
17705444
9.

Antiproliferative activity and mechanism of action of fatty acid derivatives of arabinofuranosylcytosine in leukemia and solid tumor cell lines.

Bergman AM, Kuiper CM, Voorn DA, Comijn EM, Myhren F, Sandvold ML, Hendriks HR, Peters GJ.

Biochem Pharmacol. 2004 Feb 1;67(3):503-11.

PMID:
15037202
11.

1-beta-D-Arabinofuranosylcytosine-5'-alkylphosphonophosphates and diphosphates: new orally active derivatives of ara-C.

Brachwitz H, Bergmann J, Fichtner I, Thomas Y, Vollgraf C, Langen P, Berdel WE.

J Lipid Res. 1998 Jan;39(1):162-72.

12.

Activation of protein kinase C by 1-beta-D-arabinofuranosylcytosine conjugates of phospholipid.

Lee KH, Jung YJ, Hong CI, Cho MH, Bai DH, Kim SH, Choi KY, Yu JH, Kim CM.

Int J Oncol. 2004 Jan;24(1):193-9.

PMID:
14654957
13.

Dual-targeting topotecan liposomes modified with tamoxifen and wheat germ agglutinin significantly improve drug transport across the blood-brain barrier and survival of brain tumor-bearing animals.

Du J, Lu WL, Ying X, Liu Y, Du P, Tian W, Men Y, Guo J, Zhang Y, Li RJ, Zhou J, Lou JN, Wang JC, Zhang X, Zhang Q.

Mol Pharm. 2009 May-Jun;6(3):905-17. doi: 10.1021/mp800218q.

PMID:
19344115
14.

Lipid nucleoside conjugates for the treatment of cancer.

Alexander RL, Kucera GL.

Curr Pharm Des. 2005;11(9):1079-89. Review.

PMID:
15853657
15.

Polyethylene glycol conjugates of methotrexate varying in their molecular weight from MW 750 to MW 40000: synthesis, characterization, and structure-activity relationships in vitro and in vivo.

Riebeseel K, Biedermann E, Löser R, Breiter N, Hanselmann R, Mülhaupt R, Unger C, Kratz F.

Bioconjug Chem. 2002 Jul-Aug;13(4):773-85.

PMID:
12121133
16.

PEG-doxorubicin conjugates: influence of polymer structure on drug release, in vitro cytotoxicity, biodistribution, and antitumor activity.

Veronese FM, Schiavon O, Pasut G, Mendichi R, Andersson L, Tsirk A, Ford J, Wu G, Kneller S, Davies J, Duncan R.

Bioconjug Chem. 2005 Jul-Aug;16(4):775-84.

PMID:
16029018
17.

Formulation, stability, and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugate of thioether phospholipid.

Hong CI, Bernacki RJ, Hui SW, Rustum Y, West CR.

Cancer Res. 1990 Jul 15;50(14):4401-6.

18.

Novel peptide conjugates for tumor-specific chemotherapy.

Langer M, Kratz F, Rothen-Rutishauser B, Wunderli-Allenspach H, Beck-Sickinger AG.

J Med Chem. 2001 Apr 26;44(9):1341-8.

PMID:
11311056
19.

Effect of fludarabine and arabinosylcytosine on multidrug resistant cells.

Michelutti A, Michieli M, Damiani D, Melli C, Ermacora A, Grimaz S, Candoni A, Russo D, Fanin R, Baccarani M.

Haematologica. 1997 Mar-Apr;82(2):143-7.

20.

Trans-4-lodo,4'-boranyl-chalcone induces antitumor activity against malignant glioma cell lines in vitro and in vivo.

Sasayama T, Tanaka K, Mizukawa K, Kawamura A, Kondoh T, Hosoda K, Kohmura E.

J Neurooncol. 2007 Nov;85(2):123-32. Epub 2007 May 26.

PMID:
17530176

Supplemental Content

Support Center